CD1A and inflammatory skin disease: Anti-CD1a blockade was able to effectively inhibit recognition of GAS-infected K562-CD1a cells by IL-22-producing polyclonal ex vivo blood T cells (Figure 2A), suggesting the possibility of therapeutic intervention in GAS-driven inflammatory skin disease.